Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression

被引：123

作者：

Ashrafizadeh, Milad ^{[1
,2
]}

Mirzaei, Sepideh ^{[3
]}

Gholami, Mohammad Hossein ^{[4
]}

Hashemi, Farid ^{[5
]}

Zabolian, Amirhossein ^{[6
]}

Raei, Mehdi ^{[7
]}

Hushmandi, Kiavash ^{[8
]}

Zarrabi, Ali ^{[2
]}

Voelcker, Nicolas H. ^{[9
,10
,11
]}

Aref, Amir Reza ^{[12
,13
]}

Hamblin, Michael R. ^{[14
,15
]}

Varma, Rajender S. ^{[16
]}

Samarghandian, Saeed ^{[17
]}

Arostegi, I. J. ^{[18
]}

Alzola, M. ^{[18
]}

Kumar, Alan Prem ^{[19
,20
,21
]}

Thakur, Vijay Kumar ^{[22
,23
]}

Nabavi, Noushin ^{[24
,25
]}

Makvandi, Pooyan ^{[26
]}

Tay, Franklin R. ^{[27
]}

Orive, Gorka ^{[18
,28
,29
,30
,31
]}

机构：

[1] Sabanci Univ, Fac Engn & Nat Sci, Univ Caddesi 27, TR-34956 Istanbul, Turkey

[2] Sabanci Univ, Nanotechnol Res & Applicat Ctr SUNUM, TR-34956 Istanbul, Turkey

[3] Islamic Azad Univ, Fac Sci, Dept Biol, Sci & Res Branch, Tehran, Iran

[4] Islamic Azad Univ, Fac Vet Med, Kazerun Branch, Kazerun, Iran

[5] Univ Tehran, Fac Vet Med, Dept Comparat Biosci, Tehran, Iran

[6] Islamic Azad Univ, Tehran Med Sci, Young Researchers & Elite Club, Tehran, Iran

[7] Baqiyatallah Univ Med Sci, Hlth Res Ctr, Life Style Inst, Tehran, Iran

[8] Univ Tehran, Fac Vet Med, Dept Food Hyg & Qual Control, Div Epidemiol, Tehran, Iran

[9] Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia

[10] CSIRO, Clayton, Vic 3168, Australia

[11] Victorian Node Australian Natl Fabricat Facil, Melbourne Ctr Nanofabricat, 151 Wellington Rd, Clayton, Vic 3168, Australia

[12] Harvard Med Sch, Belfer Ctr Appl Canc Sci, Dana Farber Canc Inst, Boston, MA 02115 USA

[13] Xsphera Biosci Inc, Dept Translat Sci, Boston, MA USA

[14] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, ZA-2028 Doornfontein, South Africa

[15] Iran Univ Med Sci, Radiobiol Res Ctr, Tehran, Iran

[16] Palacky Univ, Reg Ctr Adv Technol & Mat, Slechtitel 27, Olomouc 78371, Czech Republic

[17] Neyshabur Univ Med Sci, Noncommunicable Dis Res Ctr, Neyshabur, Iran

[18] Univ Basque Country, Sch Pharm, UPV EHU, NanoBioCel Res Grp, Vitoria, Spain

[19] Natl Univ Singapore, NUS Ctr Canc Res N2CR, Yong Loo Lin Sch Med, Singapore 117600, Singapore

[20] Natl Univ Singapore, Yong Loo Lin Sch Med, Canc Sci Inst Singapore, Singapore 117599, Singapore

[21] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117599, Singapore

[22] Scotlands Rural Coll SRUC, Biorefining & Adv Mat Res Ctr, Kings Bldg, Edinburgh EH9 3JG, Midlothian, Scotland

[23] Shiv Nadar Univ, Sch Engn, Dept Mech Engn, Greater Noida 201314, Uttar Pradesh, India

[24] Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H3Z6, Canada

[25] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V6H3Z6, Canada

[26] Ist Italiano Tecnol, Ctr Mat Interfaces, Viale Rinaldo Piaggio 34, I-56025 Pisa, Italy

[27] Augusta Univ, Grad Sch, Augusta, GA 30912 USA

[28] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Vitoria, Spain

[29] Univ Basque Country, Univ Inst Regenerat Med & Oral Implantol UIRMI, Fdn Eduardo Anitua, Vitoria, Spain

[30] Bioaraba, NanoBioCel Res Grp, Vitoria, Spain

[31] Singapore Eye Res Inst, 20 Coll Rd,Discovery Tower, Singapore, Singapore

来源：

CARBOHYDRATE POLYMERS | 2021年 / 272卷

基金：

新加坡国家研究基金会;

关键词：

CD44; Doxorubicin; Drug resistance; Endocytosis; Hyaluronic acid; Nanodelivery system; Theranostic; MESOPOROUS SILICA NANOPARTICLES; TARGETED DRUG-DELIVERY; FUNCTIONALIZED GRAPHENE OXIDE; HUMAN GASTRIC-CANCER; LONG NONCODING RNAS; IN-VITRO EVALUATION; LUNG-CANCER; CONTROLLED-RELEASE; CHITOSAN NANOPARTICLES; HYBRID NANOPARTICLES;

D O I：

10.1016/j.carbpol.2021.118491

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.

引用

页数：21

共 50 条

[41] pH-responsive hyaluronic acid-based nanoparticles for targeted curcumin delivery and enhanced cancer therapy
Lai, Hualu
Ding, Xin
Ye, Junxian
Deng, Jie
Cui, Shengmiao
COLLOIDS AND SURFACES B-BIOINTERFACES, 2021, 198
[42] Design and self-assembly of albumin nanoclusters as a dynamic-covalent targeting co-delivery and stimuli-responsive controlled release platform
Liu, Wen
Dai, Jian
Xue, Wei
JOURNAL OF MATERIALS CHEMISTRY B, 2018, 6 (42) : 6817 - 6830
[43] Polymeric nanoparticles based on chitooligosaccharide as drug carriers for co-delivery of all-trans-retinoic acid and paclitaxel
Zhang, Jing
Han, Jian
Zhang, Xiuli
Jiang, Jing
Xu, Maolei
Zhang, Daolai
Han, Jingtian
CARBOHYDRATE POLYMERS, 2015, 129 : 25 - 34
[44] Bioactive Lipids-Based pH Sensitive Micelles for Co-Delivery of Doxorubicin and Ceramide to Overcome Multidrug Resistance in Leukemia
Wang, Yongzhong
Ding, Yunfei
Liu, Ziming
Liu, Xingrong
Chen, Li
Yan, Weili
PHARMACEUTICAL RESEARCH, 2013, 30 (11) : 2902 - 2916
[45] Polylactic acid based biodegradable hybrid block copolymeric nanoparticle mediated co-delivery of salinomycin and doxorubicin for cancer therapy
Anees, Mohd
Mehrotra, Neha
Tiwari, Sachchidanand
Kumar, Dinesh
Kharbanda, Surender
Singh, Harpal
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 635
[46] Recent advances of hyaluronic acid-based materials in drug delivery systems and regenerative medicine: A review
Saadh, Mohamed J.
Ahmed, Hanan Hassan
Kareem, Radhwan Abdul
Bishoyi, Ashok Kumar
Roopashree, R.
Shit, Debasish
Arya, Renu
Joshi, Kamal Kant
Sameer, Hayder Naji
Yaseen, Ahmed
Athab, Zainab H.
Adil, Mohaned
Narmani, Asghar
Farhood, Bagher
ARCHIV DER PHARMAZIE, 2025, 358 (03)
[47] Binding and Internalization in Receptor-Targeted Carriers: The Complex Role of CD44 in the Uptake of Hyaluronic Acid-Based Nanoparticles (siRNA Delivery)
de la Rosa, Julio M. Rios
Pingrajai, Ponpawee
Pelliccia, Maria
Spadea, Alice
Lallana, Enrique
Gennari, Arianna
Stratford, Ian J.
Rocchia, Walter
Tirella, Annalisa
Tirelli, Nicola
ADVANCED HEALTHCARE MATERIALS, 2019, 8 (24)
[48] Tumor Microenvironment Responsive Nanomicelle with Folic Acid Modification Co-Delivery of Doxorubicin/Shikonin for Triple Negative Breast Cancer Treatment
Zhong, Wu
Shen, Zhehao
Wang, Menglan
Wang, Hongyi
Sun, Yuting
Tao, Xiaojun
Hou, Defu
PHARMACEUTICALS, 2023, 16 (03)
[49] Development of pH-Responsive Hyaluronic Acid-Based Antigen Carriers for Induction of Antigen-Specific Cellular Immune Responses
Miyazaki, Maiko
Yuba, Eiji
Hayashi, Hiroshi
Harada, Atsushi
Kono, Kenji
ACS BIOMATERIALS SCIENCE & ENGINEERING, 2019, 5 (11): : 5790 - 5797
[50] Hyaluronic acid-based drug nanocarriers as a novel drug delivery system for cancer chemotherapy: A systematic review
Nader Salari
Kamran Mansouri
Elahe Valipour
Farzaneh Abam
Mehdi Jaymand
Shna Rasoulpoor
Sadat Dokaneheifard
Masoud Mohammadi
DARU Journal of Pharmaceutical Sciences, 2021, 29 : 439 - 447

← 1 2 3 4 5 →